Qiagen N.V.
QGEN
Classement en actions
#2146
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Prix de l'action
$46.38
Capitalisation boursière
$9.56B
Changement (1 jour)
0.45%
Changement (1 an)
-3.92%
Pays
NL
Échange Qiagen N.V. (QGEN)
Catégorie
Healthcare
Marge opérationnelle de Qiagen N.V. (QGEN)
Marge opérationnelle au October 2026 TTM : 25.33%
Selon les derniers rapports financiers et le cours de l'action de Qiagen N.V., la marge opérationnelle actuelle (TTM) est de 25.33%. À la fin de 2024, elle était de 4.94%.
Historique de la marge opérationnelle pour Qiagen N.V. de 2000 à 2026
Marge opérationnelle à la fin de chaque année
| Année | Marge opérationnelle | Changez |
|---|---|---|
| 2026 (TTM) | 25.33% | 1.73% |
| 2025 | 24.90% | 404.05% |
| 2024 | 4.94% | -76.32% |
| 2023 | 20.86% | -15.95% |
| 2022 | 24.82% | -11.29% |
| 2021 | 27.98% | 35.43% |
| 2020 | 20.66% | -1,308.19% |
| 2019 | -1.71% | -109.63% |
| 2018 | 17.75% | 64.05% |
| 2017 | 10.82% | 46.41% |
| 2016 | 7.39% | -47.25% |
| 2015 | 14.01% | 16.56% |
| 2014 | 12.02% | 147.33% |
| 2013 | 4.86% | -64.11% |
| 2012 | 13.54% | 59.11% |
| 2011 | 8.51% | -50.92% |
| 2010 | 17.34% | -2.86% |
| 2009 | 17.85% | 9.44% |
| 2008 | 16.31% | 27.52% |
| 2007 | 12.79% | -40.79% |
| 2006 | 21.60% | -9.24% |
| 2005 | 23.80% | 7.64% |
| 2004 | 22.11% | 12.81% |
| 2003 | 19.60% | 35.55% |
| 2002 | 14.46% | -28.66% |
| 2001 | 20.27% | 13.18% |
| 2000 | 17.91% | 0.00% |
Marge opérationnelle pour des entreprises similaires ou concurrentes
| Entreprise | Marge opérationnelle | Différence de Marge Opérationnelle | Pays |
|---|---|---|---|
| 17.97% | -99.29% |
US
|
|
| 20.42% | -99.19% |
US
|
|
| -10.70% | -100.42% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -99.12% |
US
|
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.